I'm just not totally convinced either way about Cytodyn management. How can experts be certain about Clinical Trial protocol eg for dosage size and how long to continue for example a weekly dose. They stopped at day 14 and failed to meet the Primary Endpoint. If critical patients had been given probably just one more set of shots in the 3rd week, then a couple million deaths might have, probably would have been prevented, and many of us would be wealthy. On the other hand, Nader P. with his passion and excitement, has made many statements that did not turn into reality, timing has been way way off. But, Leronlimab is a miracle drug, and in spite of any shortcomings in management, Cytodyn will soon fly, and is absolutely a life changing investment. Without critical covid19 approval, Cytodyn is a life changing investment. Critical covid19 will just be icing on the cake. Longhaulers IMO, will be the meat of the short and mid term revenue, with cancer and NASH taking over as leaders in the long run.

One dollar per share? Oh goodness Mamamia, carumba, vamanos comprarlo ahoraita amigos.